mitophagy

Overview

Mitophagy is a highly selective form of autophagy in which damaged, dysfunctional, or superfluous mitochondria are sequestered within double-membrane vesicles called mitophagosomes and delivered to lysosomes for enzymatic degradation. As a cornerstone of mitochondrial quality control (MQC), mitophagy functions as a cellular surveillance mechanism that prevents the accumulation of depolarized or reactive oxygen species (ROS)-generating mitochondria, thereby preserving energy metabolism, redox homeostasis, and overall cell viability. The most extensively characterized pathway is the PINK1–Parkin axis, in which the serine/threonine kinase PINK1 accumulates on the outer membrane of damaged mitochondria (those with dissipated mitochondrial membrane potential) and recruits the E3 ubiquitin ligase Parkin, triggering ubiquitin-mediated cargo recognition and autophagosome formation. Additional receptor-mediated pathways, such as those involving BNIP3 and NIX, operate independently of Parkin and respond to hypoxic or developmental signals. Collectively, these pathways regulate the selective elimination of damaged mitochondria and maintain mitochondrial homeostasis within the cell.

Beyond its housekeeping role, mitophagy is tightly integrated with broader cellular stress-response pathways, influencing oxidative stress, inflammation, cellular senescence, and cell fate decisions including apoptosis and ferroptosis. Disruption of mitophagy—whether through impaired initiation, blocked autophagosome–lysosome fusion, or lysosomal dysfunction—underlies the pathogenesis of a wide spectrum of diseases, including neurodegenerative disorders, metabolic diseases, cardiovascular conditions, and pulmonary injury. Conversely, excessive or dysregulated mitophagy can itself drive pathological outcomes, underscoring its fundamentally dual role in health and disease.

Recent Publications Summary

Recent publications have positioned mitophagy as a recurring mechanism in diverse disease contexts, especially cardiometabolic, renal, and neurodegenerative disorders. In diabetic cardiomyopathy, multi-omics profiling of human hearts identified coupled dysregulation in lipid metabolism, mitophagy, and extracellular matrix remodeling, suggesting that altered mitochondrial quality control is part of the molecular landscape of diabetic heart disease 42152039May. A broader review of cardiomyopathy likewise emphasized autophagy and mitophagy as central to maintaining cardiac homeostasis and as potential diagnostic and therapeutic targets in heart failure and related cardiomyopathies 41944523Apr.

Several recent studies focused on mitophagy as a therapeutic target in kidney disease and fibrosis. In chronic kidney disease, QingShen granules were reported to activate mitophagy and suppress renal tubular epithelial-mesenchymal transition through the miR-23b-5p/Nrf2/PINK1 axis, linking mitophagy to anti-fibrotic effects 41794259Mar. A separate review on diabetic kidney disease described impaired mitophagy as part of early mitochondrial dysfunction in diabetic kidneys and highlighted mitochondrial quality control as a promising therapeutic avenue 41633353Feb. In chronic wound healing, a mitochondria-targeted co-assembled nanosystem was designed to reduce mtDNA-mediated inflammatory signaling, and mitophagy was upregulated as the final step to selectively eliminate damaged mitochondria and help suppress inflammation 41512500Jan.

Mitophagy has also been discussed in neurological disease and treatment-related cognitive impairment. In Alzheimer’s disease, a review proposed that impaired mitophagy may disrupt redox and iron homeostasis, thereby increasing neuronal susceptibility to ferroptosis, and described a self-amplifying cycle between mitophagy dysfunction, ferroptosis, and mitochondrial damage; potential interventions included Urolithin A and ferroptosis inhibitors 41823685Mar. Another review on chemotherapy-related cognitive impairment identified mitophagy as one of the core pillars of mitochondrial quality control affected by multiple chemotherapeutic classes, with downstream consequences including neuroinflammation, blood-brain barrier disruption, synaptic loss, and cognitive dysfunction 41723889Feb.

One publication reported an expression of concern for a study claiming that electroacupuncture at GV20–GB7 regulates mitophagy to protect against neurological deficits after intracerebral hemorrhage via inhibition of apoptosis; however, the notice highlighted possible data presentation issues and did not confirm the findings 41930483Apr.

What Changes, What Holds

1. Mitophagy now appears as a shared node in cardiometabolic disease remodeling rather than only a general quality-control pathway
NEW DIRECTION Multi-omics and review-level work extend the baseline by placing mitophagy in the molecular landscape of diabetic cardiomyopathy and broader cardiomyopathy/heart failure, where it tracks with lipid metabolism and extracellular matrix remodeling. This does not displace the established role in mitochondrial quality control; it adds disease-specific relevance and suggests mitophagy may be useful as a biomarker or therapeutic handle in cardiac remodeling 42152039May41944523Apr.

2. Mitophagy is being leveraged as an anti-fibrotic and anti-inflammatory strategy in kidney and wound disease
NEW DIRECTION Recent work broadens the baseline’s disease list by tying mitophagy activation to suppression of renal tubular epithelial-mesenchymal transition in chronic kidney disease and to dampening mtDNA-driven inflammation in chronic wound repair. The established account already links mitophagy failure to disease, so these studies mainly strengthen the idea that restoring mitophagy can be therapeutically useful, while also showing a more explicit anti-fibrotic and immunomodulatory role 41794259Mar41512500Jan.

3. Mitophagy dysfunction is now linked to ferroptosis and treatment-related cognitive injury, expanding its downstream consequences
NEW DIRECTION These reviews extend the baseline beyond apoptosis and general stress responses by arguing that impaired mitophagy can destabilize redox and iron homeostasis, promoting ferroptosis in Alzheimer’s disease, and by placing mitophagy among the mitochondrial quality-control processes disrupted by chemotherapy-related cognitive impairment. That adds a new disease mechanism and a new cell-death connection, but it does not contradict the established view that mitophagy influences cell fate and neurodegeneration 41823685Mar41723889Feb.

4. Claims that electroacupuncture protects the brain by regulating mitophagy remain unconfirmed
METHOD The expression of concern does not add biological knowledge so much as it weakens confidence in a specific experimental claim about mitophagy modulation after intracerebral hemorrhage. Because the notice flags possible data issues without validating the result, it should not be treated as support for a new mechanism; at most it marks an unsettled, potentially unreliable line of evidence 41930483Apr.

Overview update candidates: mitophagy as a disease-linked node in cardiomyopathy/heart failure; therapeutic activation in kidney fibrosis and wound inflammation; and a mitophagy–ferroptosis connection in Alzheimer’s disease.